Style | Citing Format |
---|---|
MLA | Moraffah F, et al.. "Advancing Burn Wound Healing With an Innovative in Situ Gelling Probiotic Microparticle Formulation Employing Quality by Design (Qbd) Principles." Journal of Tissue Viability, vol. 34, no. 2, 2025, pp. -. |
APA | Moraffah F, Samadi N, Abdollahi M, Ostad SN, Dolatabadi R, Pirouzzadeh M, Vatanara A (2025). Advancing Burn Wound Healing With an Innovative in Situ Gelling Probiotic Microparticle Formulation Employing Quality by Design (Qbd) Principles. Journal of Tissue Viability, 34(2), -. |
Chicago | Moraffah F, Samadi N, Abdollahi M, Ostad SN, Dolatabadi R, Pirouzzadeh M, Vatanara A. "Advancing Burn Wound Healing With an Innovative in Situ Gelling Probiotic Microparticle Formulation Employing Quality by Design (Qbd) Principles." Journal of Tissue Viability 34, no. 2 (2025): -. |
Harvard | Moraffah F et al. (2025) 'Advancing Burn Wound Healing With an Innovative in Situ Gelling Probiotic Microparticle Formulation Employing Quality by Design (Qbd) Principles', Journal of Tissue Viability, 34(2), pp. -. |
Vancouver | Moraffah F, Samadi N, Abdollahi M, Ostad SN, Dolatabadi R, Pirouzzadeh M, et al.. Advancing Burn Wound Healing With an Innovative in Situ Gelling Probiotic Microparticle Formulation Employing Quality by Design (Qbd) Principles. Journal of Tissue Viability. 2025;34(2):-. |
BibTex | @article{ author = {Moraffah F and Samadi N and Abdollahi M and Ostad SN and Dolatabadi R and Pirouzzadeh M and Vatanara A}, title = {Advancing Burn Wound Healing With an Innovative in Situ Gelling Probiotic Microparticle Formulation Employing Quality by Design (Qbd) Principles}, journal = {Journal of Tissue Viability}, volume = {34}, number = {2}, pages = {-}, year = {2025} } |
RIS | TY - JOUR AU - Moraffah F AU - Samadi N AU - Abdollahi M AU - Ostad SN AU - Dolatabadi R AU - Pirouzzadeh M AU - Vatanara A TI - Advancing Burn Wound Healing With an Innovative in Situ Gelling Probiotic Microparticle Formulation Employing Quality by Design (Qbd) Principles JO - Journal of Tissue Viability VL - 34 IS - 2 SP - EP - PY - 2025 ER - |